Keros CEO sells 7,015 shares in tax sale

Keros Therapeutics chief executive officer Jasbir Seehra reported an open-market sale of 7,015 shares of common stock on February 19, 2026 at $16.17 per share.

Rhea-AI Filing Summary

Keros Therapeutics chief executive officer Jasbir Seehra reported an open-market sale of 7,015 shares of common stock on February 19, 2026 at $16.17 per share. After this transaction, his directly held stake was 385,708 shares.

According to the disclosure, this was an automatic "sell-to-cover" transaction to satisfy tax withholding obligations triggered by the vesting of restricted stock units, and was not executed at his discretion.

Insider Trade Summary

Net Seller: 7,015 shares

Net Sell 1 txn

Insider Seehra Jasbir

Role CHIEF EXECUTIVE OFFICER

Sold 7,015 shs ($113K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,015	$16.17	$113K

Holdings After Transaction: Common Stock — 385,708 shares (Direct)

Footnotes (1)

1. F1. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Keros Therapeutics (KROS) report for Jasbir Seehra?

Keros Therapeutics reported that CEO Jasbir Seehra sold 7,015 shares of common stock on February 19, 2026 at $16.17 per share. The transaction was linked to tax withholding on vested restricted stock units rather than a discretionary share sale.

Why did Keros Therapeutics CEO Jasbir Seehra sell 7,015 KROS shares?

The 7,015-share sale by CEO Jasbir Seehra was carried out under a sell-to-cover policy to satisfy tax withholding obligations from vesting restricted stock units. The sales were automatic and not made at his discretion, according to the disclosure footnote.

How many Keros Therapeutics shares does CEO Jasbir Seehra hold after the latest Form 4?

After the February 19, 2026 transaction, CEO Jasbir Seehra directly held 385,708 shares of Keros Therapeutics common stock. This figure reflects his ownership following the automatic sale of 7,015 shares to cover tax withholding on vested restricted stock units.

Was the Keros Therapeutics (KROS) insider sale a discretionary trade?

No, the reported sale was not discretionary. Keros Therapeutics disclosed that the 7,015 shares sold for CEO Jasbir Seehra were part of an automatic sell-to-cover policy to meet tax withholding obligations arising from the vesting of restricted stock units.

What price was received in the Keros Therapeutics CEO’s February 19, 2026 share sale?

The shares sold for CEO Jasbir Seehra on February 19, 2026 were transacted at $16.17 per share. These open-market sales were executed solely to cover tax withholding on newly vested restricted stock units under the company’s sell-to-cover policy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 04:15 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Seehra Jasbir

(Last) (First) (Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		S		7,015(1)	D	$16.17	385,708	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

	/s/ Keith Regnante, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.